Abstract |
Patients with active distal proctitis received either 5-aminosalicylic (5-ASA) acid or identical placebo suppositories, 500 mg t.i.d. for 6 weeks. Activity at 3 and 6 wks was assessed using a Disease Activity Index (DAI), derived from four categories: number of daily evacuations more than usual, evacuations containing blood, sigmoidoscopy appearance, and physician's overall assessment. Each category was graded 0-3. There was thus 0-12 points scored ranging from complete remission to severe disease. A minimum score of 3 from two categories was necessary for study entry. Of 27 patients randomized, 14 received active medication and 13 placebo. Of the 14 patients, with initial mean DAI 7.1 +/- 1.8, 11 were in complete remission at 6 wks (78.6%). Whereas, there was no significant change in the placebo group, with initial mean DAI 7.1 +/- 1.8. An additional 6 patients with inflammatory bowel disease and 6 healthy volunteers were given 99mTc-labelled 5-aminosalicylic acid suppositories. The extent of spread was limited to the rectum, and the suppositories were retained for 3 hours. There was no absorbed radioactivity. 5-ASA suppositories are safe, well-tolerated, and effective treatment for active distal proctitis.
|
Authors | C N Williams, G Haber, J A Aquino |
Journal | Digestive diseases and sciences
(Dig Dis Sci)
Vol. 32
Issue 12 Suppl
Pg. 71S-75S
(Dec 1987)
ISSN: 0163-2116 [Print] United States |
PMID | 3319461
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Aminosalicylic Acids
- Suppositories
- Mesalamine
- Technetium
|
Topics |
- Administration, Rectal
- Adult
- Aminosalicylic Acids
(administration & dosage, therapeutic use)
- Clinical Trials as Topic
- Double-Blind Method
- Female
- Humans
- Male
- Mesalamine
- Proctitis
(drug therapy)
- Prospective Studies
- Radionuclide Imaging
- Random Allocation
- Rectum
(diagnostic imaging)
- Suppositories
- Technetium
- Time Factors
|